Edwards Lifesciences Corp (EW)
Edwards Lifesciences Corp (EW) carries a ŷRobot AI score of 53 out of 100. The model's fair value estimate is $99.70, 7.0% below the last close of $107.18. The chart signal reads Sell.
| Metric | EW |
|---|---|
| AI score | 53 / 100 |
| Chart signal | Sell |
| Fair value estimate | $99.70 |
| Upside to fair value | -7.0% |
| Previous close | $107.18 |
| P/E | 60.01 |
| Price / sales | 8.92 |
| Market cap | $60.84B |
| EPS | 1.68 |
| Revenue growth | 2.6% |
| 1-year price change | 6.7% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about EW
Is EW overvalued or undervalued right now?
As of Nov 6, 2026, ŷRobot's fair-value model estimates Edwards Lifesciences Corp (EW) at $99.70 against a last close of $107.18, implying 7.0% downside to the model's estimate.
Is EW's chart signal bullish or bearish?
The chart-signal model classifies EW as Neutral as of Nov 13, 2026, with a signal score of -0.12 on a -1 to 1 scale.
What is EW's ŷRobot AI score?
EW scores 53 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is EW stock expensive on P/E and P/S?
EW trades at 60.0 times earnings and 8.9 times sales as of Nov 13, 2026.
What does EW's seasonal forecast show?
ŷRobot's seasonal forecast curve for EW reads +3.6% at 30 days, +7.4% at 90 days, and +6.7% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is EW growing?
Edwards Lifesciences Corp's revenue growth is +2.6% and free-cash-flow growth is +9.0% on the latest reported figures.
EW chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.